welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Emflaza Supply Not Affected by COVID-19 Pandemic, PTC Therapeutics Says


The supply of Emflaza (deflazacort), a treatment for people with Duchenne muscular dystrophy (DMD), will not be affected by the COVID-19 pandemic, according to PTC Therapeutics, its developer.

In a statement addressed to patients and health care professionals, released March 16, PTC said it has more than year’s supply of Emflaza in stock and available for delivery.

COVID-19, which stands for COrona VIrus Disease 2019, is an infectious disease caused by a coronavirus. The virus is thought to spread mainly from person-to-person in small droplets of moisture that are produced by sneezing or coughing. Yet, a person also may become infected by touching a surface or object that has the virus and then touching the mouth, nose, or eyes.

The major symptoms of COVID-19 include fever, dry cough, and difficulty breathing, which may appear 2-14 days after exposure to the virus.

 

Emflaza Supply Not Affected By COVID-19 Pandemic, PTC Therapeutics Says